Published in J Neuroinflammation on July 02, 2004
Long-term pioglitazone treatment improves learning and attenuates pathological markers in a mouse model of Alzheimer's disease. J Alzheimers Dis (2012) 1.03
The Nuclear Receptor PPARgamma as a Therapeutic Target for Cerebrovascular and Brain Dysfunction in Alzheimer's Disease. Front Aging Neurosci (2010) 0.93
Effects of long-term pioglitazone treatment on peripheral and central markers of aging. PLoS One (2010) 0.90
Intact memory in TGF-β1 transgenic mice featuring chronic cerebrovascular deficit: recovery with pioglitazone. J Cereb Blood Flow Metab (2010) 0.88
Nuclear receptors in neurodegenerative diseases. Neurobiol Dis (2014) 0.85
Simvastatin restored vascular reactivity, endothelial function and reduced string vessel pathology in a mouse model of cerebrovascular disease. J Cereb Blood Flow Metab (2015) 0.80
Combined Liver X Receptor/Peroxisome Proliferator-activated Receptor γ Agonist Treatment Reduces Amyloid β Levels and Improves Behavior in Amyloid Precursor Protein/Presenilin 1 Mice. J Biol Chem (2015) 0.79
Nonsurgical therapy for hydrocephalus: a comprehensive and critical review. Fluids Barriers CNS (2016) 0.78
Therapeutic potential of nuclear receptor agonists in Alzheimer's disease. J Lipid Res (2017) 0.75
Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med (2001) 7.85
Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann Neurol (1999) 7.69
Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci (2000) 4.14
TGF-beta1 promotes microglial amyloid-beta clearance and reduces plaque burden in transgenic mice. Nat Med (2001) 3.84
Review: history of the amyloid fibril. J Struct Biol (2000) 3.49
Cerebral amyloid angiopathy and cognitive function: the HAAS autopsy study. Neurology (2002) 2.42
Endogenous beta-amyloid production in presenilin-deficient embryonic mouse fibroblasts. Nat Cell Biol (2001) 2.22
Estrogen reduces neuronal generation of Alzheimer beta-amyloid peptides. Nat Med (1998) 2.20
Inflammatory mechanisms in Alzheimer's disease: inhibition of beta-amyloid-stimulated proinflammatory responses and neurotoxicity by PPARgamma agonists. J Neurosci (2000) 2.03
Amyloidogenic role of cytokine TGF-beta1 in transgenic mice and in Alzheimer's disease. Nature (1997) 1.99
Pathogenesis, diagnosis and treatment of systemic amyloidosis. Philos Trans R Soc Lond B Biol Sci (2001) 1.89
Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis. Ann Neurol (2002) 1.86
An important role of heparan sulfate proteoglycan (Perlecan) in a model system for the deposition and persistence of fibrillar A beta-amyloid in rat brain. Neuron (1994) 1.77
Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. J Neurochem (2002) 1.61
Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice. Neurobiol Aging (2001) 1.59
Local neuroinflammation and the progression of Alzheimer's disease. J Neurovirol (2002) 1.59
Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene. Nat Med (1997) 1.56
Reversal of acute and chronic synovial inflammation by anti-transforming growth factor beta. J Exp Med (1993) 1.52
Capillary and arterial cerebral amyloid angiopathy in Alzheimer's disease: defining the perivascular route for the elimination of amyloid beta from the human brain. Neuropathol Appl Neurobiol (2003) 1.52
Increased central nervous system production of extracellular matrix components and development of hydrocephalus in transgenic mice overexpressing transforming growth factor-beta 1. Am J Pathol (1995) 1.47
Prominent cerebral amyloid angiopathy in transgenic mice overexpressing the london mutant of human APP in neurons. Am J Pathol (2000) 1.42
Chronic overproduction of transforming growth factor-beta1 by astrocytes promotes Alzheimer's disease-like microvascular degeneration in transgenic mice. Am J Pathol (2000) 1.39
Sporadic and familial cerebral amyloid angiopathies. Brain Pathol (2002) 1.33
Calpain activity regulates the cell surface distribution of amyloid precursor protein. Inhibition of calpains enhances endosomal generation of beta-cleaved C-terminal APP fragments. J Biol Chem (2002) 1.31
The peroxisome proliferator-activated receptor(PPARgamma) as a regulator of monocyte/macrophage function. J Leukoc Biol (1999) 1.28
Brain parenchymal and microvascular amyloid in Alzheimer's disease. Brain Pathol (1996) 1.26
Peroxisome proliferator-activated receptor-gamma ligands reduce neuronal inducible nitric oxide synthase expression and cell death in vivo. J Neurosci (2000) 1.25
Astroglial overproduction of TGF-beta 1 enhances inflammatory central nervous system disease in transgenic mice . J Neuroimmunol (1997) 1.17
Transforming growth factor-beta 1 potentiates amyloid-beta generation in astrocytes and in transgenic mice. J Biol Chem (2003) 1.17
Dense-core senile plaques in the Flemish variant of Alzheimer's disease are vasocentric. Am J Pathol (2002) 1.11
Normal brain development in PS1 hypomorphic mice with markedly reduced gamma-secretase cleavage of betaAPP. Neurobiol Aging (2002) 1.10
Cerebral amyloid angiopathy and vessel dysfunction. Cerebrovasc Dis (2002) 1.08
Altered formation and bulk absorption of cerebrospinal fluid in FGF-2-induced hydrocephalus. Am J Physiol (1999) 1.05
Microglial activation induces cell death, inhibits neurite outgrowth and causes neurite retraction of differentiated neuroblastoma cells. Exp Brain Res (2003) 1.04
Cerebral amyloid angiopathy: pathogenesis and effects on the ageing and Alzheimer brain. Neurol Res (2003) 1.01
Astrocyte activation and apoptosis: their roles in the neuropathology of HIV infection. Brain Pathol (2003) 1.01
Amyloid beta plaque-associated proteins C1q and SAP enhance the Abeta1-42 peptide-induced cytokine secretion by adult human microglia in vitro. Acta Neuropathol (2002) 1.01
Cerebrovascular degeneration is related to amyloid-beta protein deposition in Alzheimer's disease. Ann N Y Acad Sci (1997) 0.98
Study of cerebrospinal fluid flow dynamics in TGF-beta 1 induced chronic hydrocephalic mice. Neurol Res (2000) 0.92
Alzheimer's disease-like cerebrovascular pathology in transforming growth factor-beta 1 transgenic mice and functional metabolic correlates. Ann N Y Acad Sci (2000) 0.90
TGF-beta and the endothelium during immune injury. Kidney Int (1997) 0.90
Serum amyloid P is not present in amyloid beta deposits of a transgenic animal model. Neuroreport (1999) 0.83
Transcriptional activation and increase in expression of Alzheimer's beta-amyloid precursor protein gene is mediated by TGF-beta in normal human astrocytes. Biochem Biophys Res Commun (2002) 0.81
Primate-like amyloid-beta sequence but no cerebral amyloidosis in aged tree shrews. Neurobiol Aging (1999) 0.80
Alleles at the Nicastrin locus modify presenilin 1- deficiency phenotype. Proc Natl Acad Sci U S A (2002) 0.79
Ultramicroscopic structures of the leptomeninx of mice with communicating hydrocephalus induced by human recombinant transforming growth factor-beta 1. Neurol Med Chir (Tokyo) (1998) 0.77
Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science (2010) 14.91
ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. Science (2012) 10.42
Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science (2011) 7.92
Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9. Nature (2011) 7.20
Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science (2006) 6.47
Macroautophagy--a novel Beta-amyloid peptide-generating pathway activated in Alzheimer's disease. J Cell Biol (2005) 4.91
ApoE promotes the proteolytic degradation of Abeta. Neuron (2008) 4.75
Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep (2006) 4.06
Lipid emulsion infusion rescues dogs from bupivacaine-induced cardiac toxicity. Reg Anesth Pain Med (2003) 3.87
Lipid emulsion is superior to vasopressin in a rodent model of resuscitation from toxin-induced cardiac arrest. Crit Care Med (2009) 3.56
Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1. J Virol (2010) 3.40
Abeta is targeted to the vasculature in a mouse model of hereditary cerebral hemorrhage with amyloidosis. Nat Neurosci (2004) 3.09
Immune and Genetic Correlates of Vaccine Protection Against Mucosal Infection by SIV in Monkeys. Sci Transl Med (2011) 3.08
Formation and maintenance of Alzheimer's disease beta-amyloid plaques in the absence of microglia. Nat Neurosci (2009) 2.85
Reversal of autophagy dysfunction in the TgCRND8 mouse model of Alzheimer's disease ameliorates amyloid pathologies and memory deficits. Brain (2011) 2.76
Lipid infusion accelerates removal of bupivacaine and recovery from bupivacaine toxicity in the isolated rat heart. Reg Anesth Pain Med (2006) 2.74
CD14 and toll-like receptors 2 and 4 are required for fibrillar A{beta}-stimulated microglial activation. J Neurosci (2009) 2.69
Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops. Proc Natl Acad Sci U S A (2012) 2.69
A cell surface receptor complex for fibrillar beta-amyloid mediates microglial activation. J Neurosci (2003) 2.63
Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization. Science (2013) 2.48
Inflammation, microglia, and Alzheimer's disease. Neurobiol Dis (2009) 2.44
Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01. J Virol (2011) 2.34
Distinct and non-redundant roles of microglia and myeloid subsets in mouse models of Alzheimer's disease. J Neurosci (2011) 2.31
Acute treatment with the PPARgamma agonist pioglitazone and ibuprofen reduces glial inflammation and Abeta1-42 levels in APPV717I transgenic mice. Brain (2005) 2.27
Extracellular amyloid formation and associated pathology in neural grafts. Nat Neurosci (2003) 2.24
The role of microglia in amyloid clearance from the AD brain. J Neural Transm (Vienna) (2010) 2.21
Microglia mediate the clearance of soluble Abeta through fluid phase macropinocytosis. J Neurosci (2009) 2.20
Microglial phagocytosis induced by fibrillar beta-amyloid and IgGs are differentially regulated by proinflammatory cytokines. J Neurosci (2005) 2.18
PPARγ/RXRα-induced and CD36-mediated microglial amyloid-β phagocytosis results in cognitive improvement in amyloid precursor protein/presenilin 1 mice. J Neurosci (2012) 2.12
Epinephrine impairs lipid resuscitation from bupivacaine overdose: a threshold effect. Anesthesiology (2009) 2.11
Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. Lancet Oncol (2004) 2.08
Attenuation of neuroinflammation and Alzheimer's disease pathology by liver x receptors. Proc Natl Acad Sci U S A (2007) 2.06
Glucose metabolism, gray matter structure, and memory decline in subjective memory impairment. Neurology (2012) 1.94
Glial cells in (patho)physiology. J Neurochem (2012) 1.89
Progressive age-related development of Alzheimer-like pathology in APP/PS1 mice. Ann Neurol (2004) 1.87
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. Alzheimers Dement (2011) 1.87
Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis. Ann Neurol (2002) 1.86
Deletion of ERK2 mitogen-activated protein kinase identifies its key roles in cortical neurogenesis and cognitive function. J Neurosci (2008) 1.84
Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Proc Natl Acad Sci U S A (2006) 1.81
Inhibition of calpains improves memory and synaptic transmission in a mouse model of Alzheimer disease. J Clin Invest (2008) 1.79
Alzheimer's-related endosome dysfunction in Down syndrome is Abeta-independent but requires APP and is reversed by BACE-1 inhibition. Proc Natl Acad Sci U S A (2009) 1.72
Mechanisms underlying the rapid peroxisome proliferator-activated receptor-γ-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer's disease. J Neurosci (2012) 1.71
Contribution of inflammatory processes to Alzheimer's disease: molecular mechanisms. Int J Dev Neurosci (2006) 1.68
PPARs in the brain. Biochim Biophys Acta (2007) 1.63
Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. J Neurochem (2004) 1.61
Peroxisome proliferator-activated receptor-gamma agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents. J Neurochem (2007) 1.61
Systemic inflammation induces apoptosis with variable vulnerability of different brain regions. J Chem Neuroanat (2005) 1.61
Rab5-stimulated up-regulation of the endocytic pathway increases intracellular beta-cleaved amyloid precursor protein carboxyl-terminal fragment levels and Abeta production. J Biol Chem (2003) 1.60
Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-gamma agonists modulate immunostimulated processing of amyloid precursor protein through regulation of beta-secretase. J Neurosci (2003) 1.56
The development of CD4 binding site antibodies during HIV-1 infection. J Virol (2012) 1.53
A pan-European study of the C9orf72 repeat associated with FTLD: geographic prevalence, genomic instability, and intermediate repeats. Hum Mutat (2013) 1.53
Cystatin C inhibits amyloid-beta deposition in Alzheimer's disease mouse models. Nat Genet (2007) 1.53
In vivo reduction of amyloid-beta by a mutant copper transporter. Proc Natl Acad Sci U S A (2003) 1.52
Locus coeruleus damage and noradrenaline reductions in multiple sclerosis and experimental autoimmune encephalomyelitis. Brain (2011) 1.50
A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice. Am J Pathol (2004) 1.50
MAP'ing CNS development and cognition: an ERKsome process. Neuron (2009) 1.49
The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice. J Neurosci (2005) 1.47
Nuclear receptors as therapeutic targets for Alzheimer's disease. Expert Opin Ther Targets (2011) 1.46
Sepsis causes neuroinflammation and concomitant decrease of cerebral metabolism. J Neuroinflammation (2008) 1.46
Noradrenergic depletion potentiates beta -amyloid-induced cortical inflammation: implications for Alzheimer's disease. J Neurosci (2002) 1.46
Specific functions for ERK/MAPK signaling during PNS development. Neuron (2011) 1.45
Nitration of tyrosine 10 critically enhances amyloid β aggregation and plaque formation. Neuron (2011) 1.42
A role for ERK MAP kinase in physiologic temporal integration in hippocampal area CA1. Learn Mem (2003) 1.42
Sensory network dysfunction, behavioral impairments, and their reversibility in an Alzheimer's β-amyloidosis mouse model. J Neurosci (2011) 1.41
Mouse and human phenotypes indicate a critical conserved role for ERK2 signaling in neural crest development. Proc Natl Acad Sci U S A (2008) 1.40
HIV-1 neutralization coverage is improved by combining monoclonal antibodies that target independent epitopes. J Virol (2012) 1.39
Long-term cognitive impairment, neuronal loss and reduced cortical cholinergic innervation after recovery from sepsis in a rodent model. Exp Neurol (2007) 1.39
The in vivo brain interactome of the amyloid precursor protein. Mol Cell Proteomics (2007) 1.38
Immunotypes of a quaternary site of HIV-1 vulnerability and their recognition by antibodies. J Virol (2011) 1.38
Microglia and inflammation in Alzheimer's disease. CNS Neurol Disord Drug Targets (2010) 1.37
Presenilin mutations in familial Alzheimer disease and transgenic mouse models accelerate neuronal lysosomal pathology. J Neuropathol Exp Neurol (2004) 1.36
Extracellular signal-regulated kinase 1 (ERK1) and ERK2 play essential roles in osteoblast differentiation and in supporting osteoclastogenesis. Mol Cell Biol (2009) 1.36
Presenilin redistribution associated with aberrant cholesterol transport enhances beta-amyloid production in vivo. J Neurosci (2003) 1.36
The ERK2 mitogen-activated protein kinase regulates the timing of oligodendrocyte differentiation. J Neurosci (2011) 1.35
Biochemically defined HIV-1 envelope glycoprotein variant immunogens display differential binding and neutralizing specificities to the CD4-binding site. J Biol Chem (2011) 1.32
Antibody-dependent cell-mediated cytotoxicity in simian immunodeficiency virus-infected rhesus monkeys. J Virol (2011) 1.32
Calpain activity regulates the cell surface distribution of amyloid precursor protein. Inhibition of calpains enhances endosomal generation of beta-cleaved C-terminal APP fragments. J Biol Chem (2002) 1.31
HIV-1 neutralizing antibodies display dual recognition of the primary and coreceptor binding sites and preferential binding to fully cleaved envelope glycoproteins. J Virol (2012) 1.30
Protective effects of a peroxisome proliferator-activated receptor-beta/delta agonist in experimental autoimmune encephalomyelitis. J Neuroimmunol (2005) 1.29
Regulation of microglial phagocytosis and inflammatory gene expression by Gas6 acting on the Axl/Mer family of tyrosine kinases. J Neuroimmune Pharmacol (2007) 1.28